Lee is presently the CEO and Chief Scientist at Action Against Age-Related Macular Degeneration (AAAMD), the leading cause of legal blindness in developed world. AAAMD’s mission is to find and enable convenient, affordable, and accessible solutions – including new drugs - to stop AMD in its early stages, before it causes sight loss.

Trained in genetics and molecular/ structural biology, he is an experienced leader in setting up partnerships and alliances with multiple stakeholders to accelerate discoveries for drug discovery. Lee designed and implemented several open science strategies in two of the largest and most successful international public-private partnerships for drug discovery – the Structural Genomics Consortium (SGC) and the European Lead Factory. Alongside his scientific endeavours, Lee also advised high-level government representatives from different countries and charitable institutions on policy and strategy to integrate scientific, societal, and economic impact. Previously Lee directed the Disease Foundations Network at the Structural Genomics Consortium (SGC) – a pioneering open science initiative, at the University of Oxford.